Using 18F-FSPG PET/CT scans to assess treatment response in esophageal cancer
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
This study is testing if a special type of scan can help find tumors and see how well treatment is working for people with advanced esophageal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06549413 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate how 18F-FSPG PET/CT imaging can detect tumors in patients with locally advanced esophageal cancer undergoing chemoradiation. The study will involve patients who have untreated esophageal carcinoma greater than 2 cm and will assess the relationship between imaging results and treatment response. Participants will undergo PET/CT scans to gather data on tumor detection and treatment efficacy without any interventional procedures.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with untreated locally advanced esophageal cancer who are scheduled to receive concurrent systemic therapy and radiation.
Not a fit: Patients who are pregnant, lactating, or have significant body weight or health issues that prevent imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method to better assess treatment responses in esophageal cancer patients, potentially leading to improved management strategies.
How similar studies have performed: While the use of PET imaging in cancer treatment assessment is established, the specific application of 18F-FSPG PET/CT in esophageal cancer treatment response is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \* ≥ 18 years of age * Patients with locally advanced esophageal cancer * Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy * Ability to provide written informed consent in accordance with institutional policies * Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical Exclusion Criteria: * \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed * Pregnant or lactating females * Have an allergy to intravenous contrast * eGFR \< 30
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Steven H Lin, MD, PHD — M.D. Anderson Cancer Center
- Study coordinator: Steven H Lin, MD, PHD
- Email: shlin@mdanderson.org
- Phone: 713-563-2300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.